Search results
Results from the WOW.Com Content Network
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine [1] which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. [2]The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope [3]) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH).
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. [6] As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting [2] [needs update] and (2) a 300 patient Phase 2 trial studying the combination of ...
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210. [1] It is often referred to as the gp100 cancer vaccine which can also include other peptides based on gp100 (for example gp100:280-288(288V ...
Rindopepimut is the epidermal growth factor receptor (EGFR)-derived peptide vaccine to treat glioblastoma multiforme (GBM). The 14-mer peptide is coupled with keyhole limpet hemocyanin (KLH), which can reduce the risk of cancer. [11] E75, GP2, and AE37 are three different HER2/neu-derived single-peptide vaccines to treat breast cancer. HER2/neu ...
Several DC-based cancer vaccines have been developed including DC loaded with, tumor peptides or whole proteins, [6] with tumor-derived mRNA or DNA., [7] DC transduced with viral vectors such as retroviruses, [8] lentiviruses [9] adenoviruses, [10] fowl pox [11] and alphaviruses containing the tumor antigen or gene of interest, whole necrotic ...
CimaVax-EGF is a vaccine used to treat cancer, specifically non-small-cell lung carcinoma (NSCLC). CIMAvax-EGF is composed of recombinant human epidermal growth factor (EGF) conjugated to a protein carrier. [2] The vaccine was developed by the Center of Molecular Immunology, Havana, Cuba, and made available to the Cuban population in 2011.
In cancer vaccines, the goal is to generate an immune response to these antigens through a vaccine. Currently, only one vaccine ( sipuleucel-T for prostate cancer) has been approved. In cell-mediated therapies like CAR-T cell therapy, immune cells are extracted from the patient, genetically engineered to recognize tumor-specific antigens, and ...
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.